Longeveron Executives to Speak at CVCT Forum on Cell Therapy Innovations
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 4 day ago0mins
- Executive Participation: Longeveron's Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will participate in multiple panel discussions at the Global Cardiovascular Clinical Trialists Forum from December 8-10, 2025, aimed at promoting evidence generation and global impact in cardiovascular clinical trials.
- Cell Therapy Innovations: Dr. Hare will discuss the importance of cell delivery routes, particularly the potential of intravenous delivery of cells/cell products, emphasizing the application of cell therapy in heart failure treatment, which could introduce new therapeutic strategies in the field.
- Multi-Stakeholder Discussions: Dr. Agafonova will engage in the CVCT multi-stakeholder think tank debate, fostering collaboration and innovation among experts from various fields to accelerate the development of cell therapies.
- Product Development Progress: Longeveron's Lomecel-B® cell therapy has received five significant FDA designations, including Orphan Drug and Fast Track designations, highlighting its potential and market value in addressing rare diseases.
LGVN.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on LGVN
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.633
Low
3.00
Averages
3.50
High
4.00
Current: 0.633
Low
3.00
Averages
3.50
High
4.00
Roth Capital
Buy
downgrade
$10 -> $3
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
See All Ratings
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to the after-hours surge in biotech stocks?
How does laromestrocel reduce neuroinflammation in Alzheimer's patients?
Will Longeveron's laromestrocel therapy gain broader FDA approvals in the future?
How might the Canadian patent impact Longeveron's market growth by 2037?